Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miles Rhyne Hoffman, CFA who wrote (300)	11/7/1996 10:25:00 PM
From: eugenic1	of 849

CYTYC CORPORATION (NASDAQ: CYTC) jumped another $3 1/8 to $17 1/4 today after adding $2 1/4 yesterday. The Food and Drug Administration ruled that the company's ThinPrep cervical cancer detection method is significantly more effective than the pap smear method, which has been used for 50 years. The company's products reduce the chance of misdiagnosis of cancer and also help doctors and technicians catch early-stage cancer more effectively. Since pre-cancerous in situ cases of cervical cancer are much more common than invasive cancer, according to the American Cancer Society, investors believe that the company stands a good chance of capturing a sizable portion of the market, which is estimated to be as large as $2 billion, according to The Wall Street Journal. If the company's product saves lives with a patented process, then it would probably have little problem charging the $20 extra for each test that the Journal cited. Putting a 2 times sales multiple on Cytec, it looks as though investors are pricing in about 5% market share for next year. How does nmp technology rate against this method?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next